14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
PMI vs TCMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas TCMD carries 36.5/100 (SELL) at $25.99 (17.7x Forward P/E, 9.4% operating margin).
Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. TCMD 36.5/100 SELL), TCMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -248.1% operating margin) and revenue trajectory (+7.1% vs. +38.6% YoY).
Competes within the Medical Devices value chain with $587.6M market capitalization and 9.4% operating margin.
OpEx & R&D Reinvestment67.6% of Rev ($241M)
90D Engineering Disclosures0 Published
Investor FAQ PMI vs TCMD Key Questions & Quantitative Answers
As of Nov 19, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas TCMD carries 36.5/100 (SELL) at $25.99 (17.7x Forward P/E, 9.4% operating margin). Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. TCMD 36.5/100 SELL), TCMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -248.1% operating margin) and revenue trajectory (+7.1% vs. +38.6% YoY).
PMI leads the Growth & Scale pillar: PMI posts +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin), compared with TCMD at +7.1% YoY revenue growth and -13.9% YoY earnings growth on $356M TTM revenue (77.0% gross margin, 9.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PMI cumulative revenue shifted N/A while TCMD shifted +135.7%. In operating R&D and SG&A reinvestment, PMI deploys N/A (0 90-day corporate R&D disclosures) versus 67.6% of Rev ($241M) (0 disclosures) for TCMD.
TCMD screens cheaper on headline valuation multiples. PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin), whereas TCMD trades at 17.7x Forward P/E, 25.5x Trailing P/E, 17.79x PEG, and 1.5x EV/Revenue (8.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PMI (0.0% ROE) versus TCMD (11.0% ROE) capital efficiency.
In options market volatility and institutional positioning, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk). By comparison, TCMD carries 54.9% implied volatility (15th %ile, Compressed (<25th %ile)), a 4.00x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.99β · 52% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.